Extrarenal effects of aldosterone

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 147-156

  Nguyen Dinh Cat, Aurelie ^a   Jaisser, Frederic ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

aldosterone; fibrogenic and proinflammatory effects; metabolic syndrome; mineralocorticoid receptor; receptor tyrosine kinases

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CARDIOVERSION; DISEASE COURSE; DYSLIPIDEMIA; ELECTROPHYSIOLOGY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RIGIDITY; SMOOTH MUSCLE; SOFT TISSUE INFLAMMATION; VASOCONSTRICTION;

ALDOSTERONE; ENDOTHELIUM, VASCULAR; HEART; HUMANS; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84857041383     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834fb25b     Document Type: Review

References (140)

1. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: Insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007; 5:e012.
2. Boldyreff B, Wehling M. Nongenomic actions of aldosterone: Mechanisms and consequences in kidney cells. Nephrol Dial Transplant 2003; 18:1693-1695. (Pubitemid 37098534)
3. Le Moellic C, Ouvrard-Pascaud A, Capurro C, et al. Early nongenomic events in aldosterone action in renal collecting duct cells: PKCa activation, mineralocorticoid receptor phosphorylation, and crosstalk with the genomic response. J Am Soc Nephrol 2004; 15:1145-1160. (Pubitemid 38525996)
4. Mihailidou AS. Nongenomic actions of aldosterone: Physiological or pathophysiological role? Steroids 2006; 71:277-280.
5. Dooley R, Harvey BJ, Thomas W. Nongenomic actions of aldosterone: From receptors and signals to membrane targets. Mol Cell Endocrinol 2011. doi:10.1016/j.mce.2011.07.019. [Epub ahead of print]
6. Gomez-Sanchez CE, Warden M, Gomez-Sanchez MT, et al. Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies. Steroids 2011; 76:1541-1545.
7. Lombés M, Oblin ME, Gasc JM, et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71:503-510.
8. Hernández-Díaz I, Giraldez T, ArnauMR, et al. The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology 2010; 151:3888-3899.
9. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010; 24:2454-2463.
10. Nguyen Dinh Cat A, Briones AM, Callera GE, et al. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 2011; 58:479-488. This study demonstrates that adipocyte-derived factors impact on proinflammatory mediators expression in vascular smooth muscle cells. This is mediated in part through aldosterone/mineralocorticoid receptor-dependent pathways, but also through aldosterone-independent mineralocorticoid receptor pathways.
11. Caprio M, Fé ve B, Claës A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21:2185-2194. (Pubitemid 47026453)
12. Caprio M, Antelmi A, Chetrite G, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152:113-125. This study demonstrates that a specific mineralocorticoid receptor antagonist, drospirenone, inhibits adipogenesis at the level of differentiation and proliferation of adipocytes, suggesting a direct role of aldosterone/ mineralocorticoid receptor activation in these processes.
13. Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against DOC/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009; 54:537-543.
14. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010; 120:3350-3364; doi: 10.1172/ JCI41080. This work demonstrates the contribution of myeloid cells to cardiovascular damage and hypertension and determined the role of mineralocorticoid receptor in modulating macrophage phenotype.
15. Farman N, Maubec E, Poeggeler B, et al. The mineralocorticoid receptor as a novel player in skin biology: Beyond the renal horizon? Exp Dermatol 2010; 19:100-107.
16. Touyz RM, Callera GE. A new look at the eye: Aldosterone and mineralocorticoid receptors as novel targets in retinal vasculopathy. Circ Res 2009; 104:9-11.
17. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: Aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 2010; 24:3405-3415.
18. Gomez-Sanchez EP. Mineralocorticoid receptors in the brain and cardiovascular regulation: Minority rule? Trends Endocrinol Metab 2011; 22:179-187.
19. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int 2011; 79:1051-1060.
20. Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat: Physiological regulation. J Biol Chem 1998; 273:4883-4891. (Pubitemid 28108638)
21. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2011. doi:10.1016/ j.mce.2011.06.038. [Epub ahead of print] This review summarizes the deleterious effects of aldosterone in the heart. The authors discuss interesting points related to the critical role of mineralocorticoid receptor antagonists in heart diseases, the importance of interaction between aldosterone and salt, angiotensin II and oxidative stress to induce fibrosis and elucidate the question of the ligand that is involved in mineralocorticoid receptor activation effects.
22. Young MJ, Rickard AJ. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol 2011. doi:10. 1016/j.mce.2011.09.008. [Epub ahead of print] This review raises the question of the role of mineralocorticoid receptor activation in macrophages. Mineralocorticoid receptor may be important for the activation of tissue macrophages and the onset of fibrosis whereas vascular mineralocorticoid receptor (endothelial cell and vascular smooth muscle cell) and macrophage mineralocorticoid receptor contribute to the increased systolic blood pressure response.
23. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248. (Pubitemid 40523144)
24. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88:906-909. (Pubitemid 32995932)
25. Tsai CT, Chiang FT, Tseng CD, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010; 55:758-770.
26. Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010; 159:1584-1594.
27. Reil JC, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2011. doi:10.1093/eurheartj/ehr266. [Epub ahead of print] This study demonstrates that chronic aldosterone treatment disturbs atrial conduction without compromised ventricular haemodynamic function and electrical remodeling, suggesting a direct role of aldosterone in the pathogenesis of atrial fibrillation.
28. Lalevee N, Rebsamen MC, Barrere-Lemaire S, et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 67:216-224. (Pubitemid 40943614)
29. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111:3025-3033. (Pubitemid 40847778)
30. 2+ current in mice. J Physiol 2005; 569:153-162. (Pubitemid 41701382)
31. Gomez AM, Rueda A, Sainte-Marie Y, et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009; 119:2179-2187.
32. Dartsch T, Fischer R, Gapelyuk A, et al. Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol 2011. doi:10.1016/ j.ijcard.2011.06.100. [Epub ahead of print]
33. De Mello WC. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst 2006; 7:40-46. (Pubitemid 43891244)
34. Qu J, Volpicelli FM, Garcia LI, et al. Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res 2009; 104:365-371.
35. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717. (Pubitemid 29407370)
36. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321. (Pubitemid 36384098)
37. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010; 17:199-204.
38. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113:267-278. (Pubitemid 47372685)
39. Li RC, Ping P, Zhang J, et al. PKCepsilon modulates NF-kappaB and AP-1 via mitogen-Activated protein kinases in adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol 2000; 279:H1679-H1689.
40. Kiyosue A, Nagata D, Myojo M, et al. Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. Hypertens Res 2011. doi: 10.1038/hr.2011.119. [Epub ahead of print]
41. Newfell BG, Iyer LK, Mohammad NN, et al. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 2011; 31:1871-1880.
42. Jaffe IZ, Newfell BG, Aronovitz M, et al. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 2010; 120:3891-3900. This study demonstrates the implication of vascular mineralocorticoid receptor activation directly through PGF synthesis in arterial remodeling after vascular injury.
43. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 2002; 161:1773-1781. (Pubitemid 35265535)
44. Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006; 20:1546-1548.
45. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13:189-197;
46. Erratum in: Nat Med 2009; 15:1093.
47. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin induced vascular changes and oxidative stress. Hypertension 2002; 40:504-510.
48. Stas S, Whaley-Connell A, Habibi J, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-Angiotensin-Aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007; 148:3773-3780. (Pubitemid 47105865)
49. Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by crosstalk between angiotensin II and aldosterone. J Mol Med 2008; 86:673-678.
50. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, et al. Crosstalk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008; 52:1060-1067.
51. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: The good, the bad, and the ugly? Pflugers Arch 2009; 458:231-246.
52. Weber KT. Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 1989; 13:1637-1652. (Pubitemid 19145564)
53. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67:1355-1364.
54. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993; 27:341-348. (Pubitemid 23116130)
55. Robert V, Van Thiem N, Cheav SL, et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994; 24:30-36. (Pubitemid 24195401)
56. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26:971-978.
57. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79:215-262. (Pubitemid 29056953)
58. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004; 145:3153-3157. (Pubitemid 38829985)
59. Brilla CG, Matsubara LS, Weber KT. Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25:563-575. (Pubitemid 23208145)
60. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143:4828-4836. (Pubitemid 35397623)
61. Garnier A, Bendall JK, Fuchs S, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004; 110:1819-1825. (Pubitemid 39299224)
62. Jaisser F, Swynghedauw B, Delcayre C. The mineralocorticoid receptor in heart: Different effects in different cells. Hypertension 2011; 57:679-680.
63. Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011; 123:400-408. The authors studied the effects of cardiomyocyte-specific mineralocorticoid receptor deficiency in transgenic mice. Mineralocorticoid receptor deletion in the heart leads to infarct healing and prevents progressive adverse cardiac remodeling, contractile dysfunction, and molecular alterations in ischemic heart failure.
64. Lother A, Berger S, Gilsbach R, et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function after chronic pressure overload. Hypertension 2011; 57:746-754. The authors compared the response to a chronic severe pressure overload in two mouse models with cell-specific deletion of mineralocorticoid receptor in cardiomyocytes or in fibroblasts. Cardiac-mineralocorticoid receptor deletion, but not in fibroblasts, prevents from ventricular dilatation and failure, after chronic pressure overload.
65. Ambroisine ML, Favre J, Oliviero P, et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-Activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 2007; 116: 2435-2443. (Pubitemid 350145078)
66. Favre J, Gao J, Zhang AD, et al. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 2011; 300:H2035-H2043. This study shows that mineralocorticoid receptor activation only in the cardiomyocytes is sufficient to induce a NOX-dependent, reactive oxygen species-mediated coronary endothelial dysfunction.
67. Samuel JL, Delcayre C. Heart failure: Aldosterone antagonists are underused by clinicians. Nat Rev Cardiol 2010; 7:125-127.
68. Dorrance AM. Are macrophages the foot soldiers in the war waged by aldosterone against the heart? Hypertension 2009; 54:451-453.
69. Takeda Y, Miyamori I, Yoneda T, et al. Production of aldosterone in isolated blood vessels. Hypertension 1995; 25:170-173.
70. DeLano FA, Schmid-Schonbein GW. Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 2004; 11:69-78. (Pubitemid 39618607)
71. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2011. doi:10.1016/j.mce.2011.06.014. [Epub ahead of print] This review explains the nongenomic and genomic effects of aldosterone in the vascular endothelial and smooth muscle cells and highlights the recent findings regarding the role of aldosterone and the mineralocorticoid receptor in vitro and in vivo.
72. Oberleithner H, Ludwig T, Riethmuller C, et al. Human endothelium: Target for aldosterone. Hypertension 2004; 43:952-956. (Pubitemid 38579897)
73. Kusche-Vihrog K, Callies C, Fels J, Oberleithner H. The epithelial sodium channel (ENaC): Mediator of the aldosterone response in the vascular endothelium? Steroids 2010; 75:544-549.
74. Fels J, Callies C, Kusche-Vihrog K, Oberleithner H. Nitric oxide release follows endothelial nanomechanics and not vice versa. Pflugers Arch 2010; 460:915-923.
75. Fels J,Oberleithner H, Kusche-Vihrog K.Menage a trois: Aldosterone, sodium and nitric oxide in vascular endothelium. Biochim Biophys Acta 2010; 1802:1193-1212.
76. Kusche-Vihrog K, Urbanova K, Blanqué A, et al. C-reactive protein makes human endothelium stiff and tight. Hypertension 2011; 57:231-237. This study unravels the role of endothelial cell stiffness in inflammatory and vascular disease and present a novel mechanism involving aldosterone/ mineralocorticoid receptor, C-reactive protein, nitric oxide and PI3K/Akt signaling in the pathophysiology of endothelial dysfunction.
77. Virdis A, Ghiadoni L, Plantinga Y, et al. C-reactive protein and hypertension: Is there a causal relationship? Curr Pharm Des 2007; 13:1693-1698. (Pubitemid 46979723)
78. Fernandes D, Assreuy J. Nitric oxide and vascular reactivity in sepsis. Shock 2008; 30:10-13.
79. Perez FR, Venegas F, Gonzalez M, et al. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension 2009; 53:1000-1007.
80. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47:312-318. (Pubitemid 43740260)
81. Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosteroneinduced oxidative stress and vascular remodeling. Hypertension 2003; 42:49-55. (Pubitemid 36849598)
82. Tasatargil A, Tekcan M, Celik-Ozenci C, et al. Aldosterone-induced endothelial dysfunction of rat aorta: Role of poly(ADP-ribose) activation. J Renin Angiotensin Aldosterone Syst 2009; 10:127-137.
83. Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 476:1-7.
84. Sanz-Rosa D, Oubina MP, Cediel E, et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: Vascular functional and structural consequences. Antioxid Redox Signal 2005; 7:1294-1301. (Pubitemid 41232527)
85. Kobayashi N, Yoshid K, Nakano S, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47:671-679. (Pubitemid 43740237)
86. Thai HM, Do BQ, Tran TD, et al. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 2006; 3:240-245.
87. Leopold JA. Rapid aldosterone signaling and vascular reactivity: Relax or don't do it. J Cardiovasc Pharmacol 2009; 54:465-467.
88. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300. (Pubitemid 23065167)
89. Park JB, Schiffrin EL. ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444-1449. (Pubitemid 34225390)
90. Sugiyama T, Yoshimoto T, Tsuchiya K, et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146:3900-3906. (Pubitemid 41175760)
91. Uhrenholt TR, Schjerning J, Hansen PB, et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 2003; 93:1258-1266. (Pubitemid 37547959)
92. Liu SL, Schmuck S, Chorazcyzewski JZ, et al. Aldosterone regulates vascular reactivity: Short-term effects mediated by phosphatidylinositol 3-kinasedependent nitric oxide synthase activation. Circulation 2003; 108:2400-2406. (Pubitemid 37413549)
93. Balfagon G, Marquez-Rodas I, Alvarez Y, et al. Aldosterone modulates neural vasomotor response in hypertension: Role of calcitonin gene-related peptide. Regul Pept 2004; 120:253-260. (Pubitemid 38726214)
94. Skøtt O, Uhrenholt TR, Schjerniog J, et al. Rapid actions of aldosterone in vascular health and disease: Friend or foe? Pharmacol Ther 2006; 2:495-507. (Pubitemid 43832004)
95. Feldman RD, Gros R. Rapid vascular effects of steroids: A question of balance? Can J Cardiol 2010; 26 (Suppl. A):22A-26A.
96. Grossmann C, Benesic A, Krug AW, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 2005; 19:1697-1710. (Pubitemid 41007884)
97. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57:442-451. This study brings the new concept of a unique aldosterone plasma membrane receptor, which is different from the classic cytosolic mineralocorticoid receptor protein and exclusively mediates rapid aldosterone signaling. However, this is still a matter of debate.
98. Wehling M, Ulsenheimer A, Schneider M, et al. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: Subcellular localization of calcium elevations by single cell imaging. Biochem Biophys Res Commun 1994; 204:475-481.
99. Christ M, Gunther A, Heck M, et al. Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. Circulation 1999; 99:1485-1491. (Pubitemid 29140916)
100. 2+ and stimulation of a plasma membrane proton conductance. Proc Natl Acad Sci USA 1996; 93:10500-10504.
101. Christ M, Meyer C, Sippel K, et al. Rapid aldosterone signaling in vascular smooth muscle cells: Involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 1995; 213:123-129.
102. Manegold JC, Falkenstein E, Wehling M, et al. Rapid aldosterone effects on tyrosine phosphorylation in vascular smooth muscle cells. Cell Mol Biol 1999; 45:805-813.
103. Krug AW, Grossmann C, Schuster C, et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278:43060-43066. (Pubitemid 37345921)
104. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005; 146:973-980. (Pubitemid 40289282)
105. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45:773-779. (Pubitemid 40418380)
106. Holzman J, Liu L, Duke BJ, et al. Transactivation of the IGF-1R by aldosterone. Am J Physiol Renal Physiol 2007; 292:F1219-F1228. (Pubitemid 46572441)
107. Grossmann C, Gekle M. Nonclassical actions of the mineralocorticoid receptor: Misuses of EGF receptors? Mol Cell Endocrinol 2007; 277:6-12. (Pubitemid 47496192)
108. Callera GE, Montezano AC, Yogi A, et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46:1032-1038.
109. Griol-Charhbili V, Fassot C, Messaoudi S, et al. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011; 57:238-244. This study provides the first demonstration that EGFR activity is a key component in the functional consequences of aldosterone in the vessel but is not involved in the structural remodeling of the vascular wall induced by aldosterone.
110. Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009; 82:261-271.
111. Mehta VB, Besner GE. Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-kappa b activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2005; 175:1911-1918. (Pubitemid 41023098)
112. Chansel D, Ciroldi M, Vandermeersch S, et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J 2006; 20:1936-1938.
113. Callera GE, Yogi A, Briones AM, et al. Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: Role of PDGFR. Cardiovasc Res 2011; 91:720-731. This study demonstrates that proinflammatory effects of aldosterone in VSMCs involve c-Src activation and trafficking to cholesterol-rich domains via PDGFR. These novel findings identify lipid rafts/caveolae as dynamic scaffolding systems for aldosterone/mineralocorticoid receptor in VSMCs and suggest important crosstalk between PDGFR and c-Src, processes that may be important in nongenomic events of aldosterone proinflammatory vascular signaling.
114. Zennaro MC, Caprio M, Fé ve B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 2009; 20:444-451.
115. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011; 3:163-172.
116. Marzolla V, Armani A, Zennaro MC, et al. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol 2011. doi:10.1016/j.mce.2011.09.011. [Epub ahead of print] This review summarizes the latest concepts on the role of the mineralocorticoid receptor in white and brown adipocytes, and highlights the potential benefits of tissue-selective mineralocorticoid receptor blockade in the treatment of obesity and metabolic syndrome.
117. Lastra G, Dhuper S, Johnson MS, et al. Salt, aldosterone, and insulin resistance: Impact on the cardiovascular system. Nat Rev Cardiol 2010; 7:577-584.
118. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: Role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010; 52:401-409.
119. Luther JM, Brown NJ. The renin-Angiotensin-Aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011; 32:734-739.
120. Ehrhart-Bornstein M, Arakelyan K, Krug AW, et al. Fat cells may be the obesity-hypertension link: Human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004; 30:865-870. (Pubitemid 40070185)
121. Kraus D, Jäger J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005; 37:455-459. (Pubitemid 41081228)
122. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150:776-783.
123. Wada T, Ohshima S, Fujisawa E, et al. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 2009; 150:1662-1669.
124. Sowers JR. Metabolic risk factors and renal disease. Kidney Int 2007; 71:719-720. (Pubitemid 46624014)
125. Stiefel P, Vallejo-Vaz AJ, García Morillo S, et al. Role of the renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011; 2011:685238.
126. Luther JM, Luo P, Kreger MT, et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011; 54:2152-2163. This study demonstrates for the first time that endogenous aldosterone regulates insulin secretion and that perturbation of aldosterone directly alters insulin secretion within beta cells. Indeed, aldosterone deficiency enhances glucosestimulated insulin secretion in vivo and that this effect is independent of electrolyte disturbance, insulin sensitivity or renin activity in an aldosterone synthase deficiency mouse model.
127. Gorzelniak K, Engeli S, Janke J, et al. Hormonal regulation of the human adipose-tissue renin-Angiotensin system: Relationship to obesity and hypertension. J Hypertens 2002; 20:965-973. (Pubitemid 34913678)
128. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-Angiotensin-Aldosterone system: Role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35:807-825. (Pubitemid 36379323)
129. Paul M, Mehr AP, Kreutz R. Physiology of local renin-Angiotensin systems. Physiol Rev 2006; 86:747-803. (Pubitemid 44033382)
130. Galic S, Oakhill JS, SteinbergGR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316:129-139.
131. Lu H, Boustany-Kari CM, Daugherty A, et al. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007; 292:E1280-E1287. (Pubitemid 46684595)
132. Sarzani R, Marcucci P, Salvi F, et al. Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes (Lond) 2007; 32:259-267. (Pubitemid 351271787)
133. Brucher R, Cifuentes M, Acuna MJ, et al. Larger antiadipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity (Silver Spring) 2007; 15:1643-1646. (Pubitemid 47264942)
134. Hsueh WA, Wyne K. Renin-Angiotensin-Aldosterone system in diabetes and hypertension. J Clin Hypertens 2011; 13:224-237.
135. Galvez B, de Castro J, Herold D, et al. Perivascular adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2006; 26:1297-1302. (Pubitemid 44305373)
136. Eringa EC, Bakker W, Smulders YM, et al. Regulation of vascular function and insulin sensitivity by adipose tissue: Focus on perivascular adipose tissue. Microcirculation 2007; 14:389-402. (Pubitemid 47050030)
137. Brandes RP. The fatter the better? Perivascular adipose tissue attenuates vascular contraction through different mechanisms. Br J Pharmacol 2007; 151:303-304. (Pubitemid 46842670)
138. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol 2009; 302:128-139.
139. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens A 1991; 13:277-296.
140. Withers SB, Agabiti-Rosei C, Livingstone DM, et al. Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat. Arterioscler Thromb Vasc Biol 2011; 31:908-913.